TW200722091A - Combinations, methods and compositions for treating cancer - Google Patents

Combinations, methods and compositions for treating cancer

Info

Publication number
TW200722091A
TW200722091A TW095113103A TW95113103A TW200722091A TW 200722091 A TW200722091 A TW 200722091A TW 095113103 A TW095113103 A TW 095113103A TW 95113103 A TW95113103 A TW 95113103A TW 200722091 A TW200722091 A TW 200722091A
Authority
TW
Taiwan
Prior art keywords
methods
compositions
combinations
treating cancer
bcr
Prior art date
Application number
TW095113103A
Other languages
English (en)
Inventor
Francis Y Lee
Roberto Weinmann
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of TW200722091A publication Critical patent/TW200722091A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW095113103A 2005-04-13 2006-04-13 Combinations, methods and compositions for treating cancer TW200722091A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67074405P 2005-04-13 2005-04-13
US74843305P 2005-12-08 2005-12-08
US11/402,502 US20060235006A1 (en) 2005-04-13 2006-04-12 Combinations, methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
TW200722091A true TW200722091A (en) 2007-06-16

Family

ID=37109315

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095113103A TW200722091A (en) 2005-04-13 2006-04-13 Combinations, methods and compositions for treating cancer

Country Status (12)

Country Link
US (2) US20060235006A1 (zh)
EP (1) EP1868435A4 (zh)
JP (1) JP2008536853A (zh)
KR (1) KR20080004495A (zh)
AU (1) AU2006236812A1 (zh)
BR (1) BRPI0608176A2 (zh)
CA (1) CA2604581A1 (zh)
EA (1) EA200702238A1 (zh)
MX (1) MX2007012537A (zh)
NO (1) NO20075087L (zh)
TW (1) TW200722091A (zh)
WO (1) WO2006113304A2 (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144910A0 (en) 1999-04-15 2002-06-30 Bristol Myers Squibb Co Cyclic compounds and pharmaceutical compositions containing the same
PL1848414T3 (pl) 2005-02-03 2011-10-31 Wyeth Llc Sposób leczenia nowotworu opornego na gefitinib
US8247419B2 (en) * 2005-06-09 2012-08-21 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant kit protein
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
WO2007059143A2 (en) * 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mdr-1 overexpression with protein tyrosine kinase inhibitors and combinations thereof
RU2452492C2 (ru) * 2006-04-05 2012-06-10 Новартис Аг КОМБИНАЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ Bcr-Abl/c-Kit/PDGF-R TK, ДЛЯ ЛЕЧЕНИЯ РАКА
AU2007235976A1 (en) * 2006-04-07 2007-10-18 Novartis Ag Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
WO2008089135A2 (en) * 2007-01-12 2008-07-24 University Of South Florida Identification of biomarkers predictive of dasatinib effects in cancer cells
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009076373A1 (en) * 2007-12-10 2009-06-18 Concert Pharmaceuticals Inc. Heterocyclic kinase inhibitors
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
WO2010014784A2 (en) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
CN102202667A (zh) * 2008-08-04 2011-09-28 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
WO2010077894A2 (en) * 2008-12-16 2010-07-08 Bristol-Myers Squibb Company Methods of inhibiting quiescent tumor proliferation
EP2456790A1 (en) * 2009-07-20 2012-05-30 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2011038467A1 (en) * 2009-10-01 2011-04-07 Csl Limited Method of treatment of philadelphia chromosome positive leukaemia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
IL144910A0 (en) * 1999-04-15 2002-06-30 Bristol Myers Squibb Co Cyclic compounds and pharmaceutical compositions containing the same
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
JP4477303B2 (ja) * 2001-05-16 2010-06-09 ノバルティス アーゲー Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよび化学療法剤を含んでなる併用剤
EP1534862A4 (en) * 2002-08-07 2007-10-10 Exelixis Inc RABGGT MODULATORS AND METHODS OF USE THEREOF
US20050009891A1 (en) * 2003-07-09 2005-01-13 Lee Francis Y. Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
MY144177A (en) * 2004-02-04 2011-08-15 Novartis Ag Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.
US7491725B2 (en) * 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TW200628156A (en) * 2004-11-04 2006-08-16 Bristol Myers Squibb Co Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases

Also Published As

Publication number Publication date
BRPI0608176A2 (pt) 2009-11-17
MX2007012537A (es) 2007-12-10
WO2006113304A2 (en) 2006-10-26
EA200702238A1 (ru) 2008-04-28
US20090054415A1 (en) 2009-02-26
KR20080004495A (ko) 2008-01-09
EP1868435A4 (en) 2009-04-01
AU2006236812A1 (en) 2006-10-26
JP2008536853A (ja) 2008-09-11
WO2006113304A3 (en) 2007-08-02
EP1868435A2 (en) 2007-12-26
CA2604581A1 (en) 2006-10-26
NO20075087L (no) 2008-01-09
US20060235006A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
TW200722091A (en) Combinations, methods and compositions for treating cancer
GEP20104927B (en) Formulations of a src/abl inhibitor
PE20061394A1 (es) Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas
AP1545A (en) Hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
AR104566A2 (es) Forma cristalina de la sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo
ATE481093T1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
WO2007125310A3 (en) Pharmaceutical combinations of pk inhibitors and other active agents
NO20084923L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
UA96126C2 (ru) Соединение для ингибирования активности rho киназы, фармацевтическая композиция, которая содержит такое соединение, и способ ингибирования активности rho киназы
EA200702568A1 (ru) Гетеробициклические ингибиторы металлопротеазы и их применение
TW200714589A (en) Phenylacetamides suitable as protein kinase inhibitors
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
EA201391705A1 (ru) Триазолпиридиновые ингибиторы 11-бета-гидроксистероиддегидрогеназы типа i
NO20081569L (no) Administrasjon av dipeptidylpeptildaseinhibitorer
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
ATE522526T1 (de) 4-(3-(2-(phenyl)morpholino)-2-oxopyrrolidin-1-y )-n-(thiazol-2-yl)benzolsulfonamidderivate und verwandte verbindungen als ionenkanalmodulatoren zur behandlung von schmerzen
NO20092412L (no) Hydantoinderivater anvendes som MMP-inhibitorer
WO2006004937A3 (en) Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other cns disorders
EP1951709A4 (en) IMIDAZOLIDINONE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS IN THE TREATMENT OF ALZHEIMER'S DISEASE
ZA200704913B (en) 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
WO2007068728A3 (en) N-substituted pyrrolopyridinones active as kinase inhibitors
WO2008011483A3 (en) Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
PE20091617A1 (es) Tiazolil-dihidro-indazoles
WO2007033374A3 (en) Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor